{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:03:51Z","timestamp":1792699431300,"version":"4.5.0"},"reference-count":58,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Skin Research and Technology"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Dopamine (D) and serotonin (5\u2010HT) pathways contribute to psoriasis pathobiology. Disruptions incite increased inflammatory mediators, keratinocyte activation and deterioration, and worsening symptoms. Brilaroxazine (RP5063), which displays potent high binding affinity to D\n                      <jats:sub>2\/3\/4<\/jats:sub>\n                      and 5\u2010HT\n                      <jats:sub>1A\/2A\/2B\/7<\/jats:sub>\n                      receptors and a moderate affinity to serotonin transporter (SERT), may affect the underlying psoriasis pathology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An imiquimod\u2010induced psoriatic mouse model (BALB\/c) evaluated brilaroxazine's activity in a topical liposomal\u2010aqueous gel (Lipogel) formulation. Two of the three groups (n\u00a0=\u00a06 per) underwent induction with 5% imiquimod, and one group received topical brilaroxazine Lipogel (Days 1\u201311). Assessments included (1) Psoriasis Area and Severity Index (PASI) scores (Days 1\u201312), skin histology for Baker score based on H&amp;E stained tissue (Day 12), and serum blood collection for serum cytokine analysis (Day 12). One\u2010way ANOVA followed by post hoc Dunnett's\n                      <jats:italic>t<\/jats:italic>\n                      \u2010test evaluated significance (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Imiquimod\u2010induced animal Baker scores were higher versus Sham non\u2010induced control's results (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Brilaroxazine Lipogel had significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.003) lower Baker scores versus the induced Psoriasis group. Brilaroxazine PASI scores were lower (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.03) versus the induced Psoriasis group (Days\u00a03\u201012), with the greatest effect in the last 3 days. The induced Psoriasis group showed higher Ki\u201067 and TGF\u2010\u03b2 levels versus non\u2010induced Sham controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.001). The brilaroxazine Lipogel group displayed lower levels of these cytokines versus the induced Psoriasis group, Ki\u201067 (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.001) and TGF\u2010\u03b2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.008), and no difference in TNF\u2010\u03b1 levels versus Sham non\u2010induced controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Brilaroxazine Lipogel displayed significant activity in imiquimod\u2010induced psoriatic animals, offering a novel therapeutic strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/srt.13606","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T08:18:46Z","timestamp":1708071526000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Brilaroxazine lipogel displays antipsoriatic activity in imiquimod\u2010induced mouse model"],"prefix":"10.1111","volume":"30","author":[{"given":"Laxminarayan","family":"Bhat","sequence":"first","affiliation":[{"name":"Reviva Pharmaceuticals, Inc.  Cupertino California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema R.","family":"Bhat","sequence":"additional","affiliation":[{"name":"Reviva Pharmaceuticals, Inc.  Cupertino California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arulprakash","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"Reviva Pharmaceuticals, Inc.  Cupertino California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthukumar","family":"Amirthalingam","sequence":"additional","affiliation":[{"name":"Reviva Pharmaceuticals, Inc.  Cupertino California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcp.2017.03.002"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184347"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0257"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115078"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14175"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2022.01.006"},{"issue":"3","key":"e_1_2_9_9_1","first-page":"889","volume":"33","author":"Biljan D","year":"2009","journal-title":"Psoriasis Ment Disord Stress"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07071.x"},{"key":"e_1_2_9_11_1","unstructured":"MoraesFA Da SilvaMRR Dos SantosJBR et\u00a0al.Health\u2010Related Quality of Life in Psoriatic Arthritis: Findings and Implications.www.elsevier.com\/locate\/vhri"},{"key":"e_1_2_9_12_1","first-page":"38","article-title":"Systemic inflammation in psoriasis: a guide for dermatology care providers","volume":"7","author":"Cantrell W","year":"2018","journal-title":"Prac Derm"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100041"},{"issue":"9","key":"e_1_2_9_14_1","first-page":"504","article-title":"The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives","volume":"9","author":"Feldman SR","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1479738"},{"key":"e_1_2_9_16_1","first-page":"1","article-title":"Biologic and small\u2010molecule therapies for moderate\u2010to\u2010severe psoriasis: focus on psoriasis comorbidities","author":"Jiang Y","year":"2023","journal-title":"BioDrugs"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_2_9_18_1","first-page":"181","volume-title":"Chapter 10 \u2010 serotonin and the immune system. In: Pilowsky PM, ed. Serotonin","author":"Roumier A","year":"2019"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-006-0652-6"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000342140"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000589"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2019.267"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022\u2010202X.2005.23873.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.03.008"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.07.013"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.05.048"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.05.052"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0472-z"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12545"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12518"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v11i4.3837"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802999"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23435.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217710637"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.080173"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.913174"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.034"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.024"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.045"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.06.001"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.318"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018266"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93396"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711680202"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1046-3"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.1997.d01-232.x"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2006.00719.x"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040796"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2015.05.044"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-002-0350-y"},{"key":"e_1_2_9_51_1","unstructured":"ThorslundK.Serotonergic mechanisms in psoriasis. Karolinska Institutet (Sweden);2012.https:\/\/openarchive.ki.se\/xmlui\/bitstream\/handle\/10616\/41011\/Thesis_Kristofer_Thorslund.pdf?sequence=1&isAllowed=y"},{"issue":"03","key":"e_1_2_9_52_1","article-title":"Topical nano drug delivery for treatment of psoriasis: progressive and novel delivery","volume":"12","author":"Aggarwal G","year":"2018","journal-title":"Asian J Pharm (AJP)"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.29245\/2572.942X\/2018\/5.1225"},{"key":"e_1_2_9_54_1","unstructured":"Safety and efficacy of brilaroxazine (RP5063) in schizophrenia\u2014full text view\u2014ClinicalTrials.gov. Accessed March 22 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05184335?term=RP5063&draw=2&rank=1"},{"key":"e_1_2_9_55_1","unstructured":"RP5063 in subjects with schizophrenia or schizoaffective disorder\u2014full text view\u2014ClinicalTrials.gov. Accessed March 22 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01490086?term=RP5063&draw=2&rank=2"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020669"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00046"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66771"},{"issue":"3","key":"e_1_2_9_59_1","first-page":"26S","article-title":"Taking personalized medicine seriously: biomarker approaches in phase IIb\/III studies in major depression and schizophrenia","volume":"12","author":"Murck H","year":"2015","journal-title":"Innov Clin Neurosci"}],"updated-by":[{"DOI":"10.1111\/srt.70329","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000}}],"container-title":["Skin Research and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/srt.13606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/srt.13606","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/srt.13606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:59:55Z","timestamp":1770832795000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/srt.13606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/srt.13606"],"URL":"https:\/\/doi.org\/10.1111\/srt.13606","archive":["Portico"],"relation":{},"ISSN":["0909-752X","1600-0846"],"issn-type":[{"value":"0909-752X","type":"print"},{"value":"1600-0846","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2024-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13606"}}